{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1","upperLimit":"17","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"description":"Time to relapse is defined as the length of time after beginning treatment until the participant has experienced a relapse in disease, measured in months.","dispersionType":"Full Range","groups":[{"description":"Patients will be stratified according to risk categories (low, standard and high), defined by GVHD status, mixed versus full donor chimerism, and positive versus negative Minimal Residual Disease (MRD) results. Patients will receive up to 7 cycles of low-dose azacitidine (40mg/m2 IV/SC daily x 4 days) at 6 weekly intervals, except for low risk ALL patients who may not receive treatment after withdrawal of immunosuppression. Standard risk patients will receive an additional 6 cycles of azacitidine alone. High risk patients will receive an additional 6 cycles of azacitidine plus escalating DLI.\n\nazacitidine: 40mg/m2 IV/SC daily x 4 days, maximum of 7 cycles at 6 weekly intervals\n\ndonor lymphocyte infusion: For patients with cells available for DLI who are in the high risk group and do not have graft-versus-host disease (GVHD), DLI will be adminstered on day 5 of each cycle.","id":"OG000","title":"Azacitidine/Donor Lymphocyte Infusion"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Median Time to Relapse","type":"SECONDARY","unitOfMeasure":"months"}